Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, et al.
Journal of Diabetes Investigation (2021) Vol. 12, Iss. 9, pp. 1586-1593
Open Access | Times Cited: 12

Showing 12 citing articles:

Update on Measuring Ketones
Jingtong Huang, Andrea M. Yeung, Richard M. Bergenstal, et al.
Journal of Diabetes Science and Technology (2023) Vol. 18, Iss. 3, pp. 714-726
Open Access | Times Cited: 14
Pharmacologic management of diabetic kidney disease and other considerations
Daniel R. Mead, Ian P Rios, Sonya Cooks, et al.
The Nurse Practitioner (2025) Vol. 50, Iss. 5, pp. 35-42
Closed Access
Update on slowly progressive type 1 diabetes
Yoichi Oikawa, Akifumi Haisa, Atsushi Satomura, et al.
Journal of Diabetes Investigation (2025)
Open Access
Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence
Alberto Maran, Federico Boscari, Carlo Fagarazzi, et al.
Journal of Endocrinological Investigation (2025)
Open Access
Sick day management in children and adolescents with diabetes
Helen Phelan, Ragnar Hanås, Sabine E. Hofer, et al.
Pediatric Diabetes (2022) Vol. 23, Iss. 7, pp. 912-925
Open Access | Times Cited: 11
SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Yujin Ma, Qian Zhao, Huifang Peng, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 5, pp. 98-98
Open Access | Times Cited: 6
Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database
Norio Abiru, Yoshino Nakatsuji, Masahiro Noguchi, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 8, pp. 697-706
Open Access | Times Cited: 4
A New Era of Diabetic Kidney Disease Treatment with Sodium–Glucose Cotransporter‐2 Inhibitors
Shinji Kume, Hiroshi Maegawa
Journal of Diabetes Investigation (2022) Vol. 13, Iss. 5, pp. 765-767
Open Access | Times Cited: 6
Off‐label use of sodium glucose co‐transporter inhibitors among adults in type 1 diabetes exchange registry
Michael S. Hughes, Ryan Bailey, Peter Calhoun, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 171-173
Closed Access | Times Cited: 7
Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis
Norio Abiru, Shingo Shoji, Yoshinori Kosakai, et al.
Diabetes Research and Clinical Practice (2022) Vol. 190, pp. 109973-109973
Open Access | Times Cited: 3
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Hikaru Kamoshima, Hiroshi Nomoto, Kumiko Yamashita, et al.
Endocrine Journal (2021) Vol. 69, Iss. 5, pp. 495-509
Open Access | Times Cited: 3
Current clinical state of type 1 diabetes in Saitama prefecture
Yoichi Oikawa, Koshi Hashimoto, Kazuo Hara, et al.
Diabetology International (2021) Vol. 13, Iss. 2, pp. 436-446
Open Access | Times Cited: 2
Page 1

Scroll to top